Hasil Pencarian  ::  Simpan CSV :: Kembali

"Pendahuluan: Deep Vein Thrombosis (DVT) memiliki kecenderungan terus meningkat dengan koinsidensi mortalitas jangka pendek dan morbiditas jangka panjang. COVID-19 dapat menyebabkan hypercoagulable state dan menjadi predisposisi terjadinya DVT. Penelitian ini bertujuan untuk menganalisis hubungan kadar fibrinogen, D-Dimer, dan dosis heparin teraupetik berdasarkan kadar APTT dengan adanya COVID-19 pada pasien DVT. Metode: Desain penelitian komparatif dan kohort prospektif digunakan untuk membandingkan kadar fibrinogen, D-Dimer, dan dosis heparin terapeutik antara pasien COVID-19 dan non COVID-19 yang menderita DVT di RSPN Cipto Mangunkusumo pada bulan Maret 2020 – Maret 2022. Penegakan diagnosis DVT dilakukan dengan pemeriksaan ultrasonografi dan/atau computed tomography angiography (CTA) fase vena. Data variabel utama dan lainnya diperoleh dari rekam medis pasien. Uji T independen atau Mann-Whitney digunakan untuk menganalisis perbedaan nilai variabel antara kedua kelompok. Hasil: Dari total 253 sampel, tidak terdapat perbedaan karakterisitik awal antara kelompok DVT COVID-19 (n=44) dan DVT non COVID-19 (n=209), kecuali pada parameter Wells Score. Kelompok DVT COVID-19 memiliki kadar Fibrinogen, D-Dimer, dan aPTT yang lebih tinggi daripada kelompok DVT non COVID-19, baik sebelum terapi maupun sesudah terapi heparanisasi (semua nilai p =0,000). Pada akhir pengamatan, didapatkan dosis heparin terapeutik pada kelompok DVT COVID-19 lebih tinggi dibanding pada kelompok DVT non COVID-19 (30,00 (20,00-40,00)x103 U vs. 25,00 (20,00-35,00)x103 U, p=0,000). Kesimpulan: Kadar fibriongen, D-Dimer, dan dosis heparin terapeutik pada pasien DVT yang menderita COVID-19 lebih tinggi dibandingkan pada pasien DVT yang tidak menderita COVID-19. Inisiasi pemberian dosis heparin terapeutik dosis tinggi dapat dipertimbangkan pada pasien DVT dengan komorbid COVID-19 dan dipandu oleh hasil pemeriksaan biomarker koagulasi darah.

---

Introduction: Deep Vein Thrombosis (DVT) has an increasing trend with a coincidence of short-term mortality and long-term morbidity. COVID-19 can cause a hypercoagulable state and predispose to DVT. This study aims to analyze the relationship between fibrinogen levels, D-Dimer, and therapeutic heparin doses based on APTT levels in the presence of COVID-19 in DVT patients. Methods: A comparative study design and a prospective cohort were used to compare levels of fibrinogen, D-Dimer, and therapeutic heparin doses between COVID-19 and non-COVID-19 patients suffering from DVT at Cipto Mangunkusumo Hospital in March 2020 – March 2022. Diagnosis of DVT was performed by ultrasound examination and/or computed tomography angiography (CTA) venous phase. The primary variable data and others were obtained from the patient's medical record. An Independent T-test or Mann-Whitney was used to analyze the differences in variable values between the two groups. Results: Of 253 samples, there was no difference in initial characteristics between the DVT COVID-19 (n=44) and non-COVID-19 DVT groups (n=209), except for the Wells Score parameter. The COVID-19 DVT group had higher levels of fibrinogen, D-Dimer, and aPTT than the non-COVID-19 DVT group, both before and after heparinization therapy (all p-values = 0.000). At the end of the follow-up period, the therapeutic dose of heparin in the COVID-19 DVT group was higher than in the non-COVID-19 DVT group (30.00 (20.00-40.00)x103 U vs. 25.00 (20.00-35.00)x103 U, p-value=0.000). Conclusion: The levels of fibrinogen, D-Dimer, and therapeutic doses of heparin in DVT patients who have COVID-19 are higher than in DVT patients who do not have COVID-19. Initiation of a higher therapeutic dose of heparin can be considered in DVT patients with comorbid COVID-19 and guided by the results of blood coagulation biomarkers."

"Latar belakang : Konduit vena lebih rentan mengalami trombosis dini dalam satu tahun pertama pasca bedah pintas arteri koroner sehingga meningkatkan risiko morbiditas maupun mortalitas. Penelitian ini bertujuan untuk meneliti ada tidaknya perbedaan kejadian trombosis dini konduit vena pascabedah pintas arteri koroner (BPAK) dengan teknik on-pump dan off-pump pada pasien non-resisten aspirin.Metode : Dilakukan suatu studi kohort prospektif pada pasien yang menjalani operasi BPAK elektif di Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita dari bulan September 2019 hingga September 2020. Penelitan ini membandingkan kejadian trombosis pada satu bulan pascabedah pada kelompok on-pump dan off-pump dengan menggunakan pemeriksaan MSCT, serta membandingkan nilai MGF dan PI pada kedua kelompok tersebut.Hasil : Sebanyak 60 konduit vena dari 28 pasien yang menjalani BPAK dilibatkan dalam penelitian ini. Sebanyak masing-masing 30 konduit pada kelompok off-pump dan on-pump. Hasil penelitian ini menunjukan tidak ada perbedaan bermakna pada kejadian trombosis dini antara kedua kelompok. Kejadian trombosis dini pada BPAK on-pump sebanyak 13,3% dan pada BPAK off-pump 13,3% (p=1). Evaluasi nilai MGF dan PI juga menunjukan hasil tidak berbeda bermakna antara kedua teknik operasi maupun pada kelompok konduit yang paten atau oklusi.Simpulan : Tidak ada perbedaan bermakna pada kejadian trombosis dini antara BPAK baik secara on pump maupun off pump

---

Introduction : Early thrombosis is more common in vein grafts and may occur within the first year after coronary artery bypass graft surgery and can increase morbidity and mortality rate. This study aims to establish whether there is a difference of the incidence of early thrombosis after on-pump and off-pump CABG in non-aspirin resistant patient population.

Method : Patients who undergone elective CABG surgery from September 2019 to September 2020 in single center was included in this prospective cohort study. This study compares the incidence of vein graft thrombosis at one month postoperative in both groups on pump and off pump using MSCT, and compares MGF and PI value of in on pump and off pump group also in patent and occluded vein grafts.

Results : A total of 60 vein grafts (30 on-pump and 30 off-pump) from 28 patients were analyzed in this study. There was no significant difference on the incidence of early vein graft thrombosis between two groups (13,3% in on pump vs 13,3% in off pump, p:1). MGF and PI value showed no difference in both techniques also no difference in patent group and occluded group

Conclusion : There is no significant difference in early vein graft thrombosis after on-pump or off-pump CABG."

"ABSTRAKLatar Belakang: Tromboemboli vena merupakan penyebab morbiditas dan mortalitas yang penting pada pasien kanker. Belum ada sistem skor untuk memprediksi TVD pada pasien tanpa gejala dan tanda trombosis. Sistem skor Wells merupakan sistem skoring yang awalnya digunakan untuk memprediksi TVD pada pasien dengan faktor risiko trombosis dan secara klinis diduga suspected TVD, tetapi, belum digunakan pada pasien-pasien yang tanpa gejala dan tanda TVD. Perlu dilakukan penelitian untuk mengetahui kegunaan skor Wells yang dilanjutkan dengan algoritma ACCP IX pada pasien kanker yang asimtomatik TVD.Tujuan: Mengetahui kegunaan skor Wells dalam mendiagnosis TVD pada pasien kanker yang tidak menunjukkan gejala dan tanda trombosis asimtomatik .Metode: Penelitian ini menggunakan metode potong lintang. Pasien kanker yang insidens trombosis vena dalamnya tinggi tanpa gejala dan tanda TVD , dihitung skor Wells dan dilanjutkan dengan algoritma diagnostik ACCP IX untuk mendiagnosis TVD.Hasil: Penelitian ini merekrut 100 pasien kanker yang memenuhi kriteria inklusi dan eksklusi, dan mendapatkan kejadian TVD pada 2 pasien kanker yang tidak menunjukkan gejala dan tanda TVD. Sebagian besar pasien 93 memiliki skor Wells unlikely < 2 . Hasil D-dimer lebih dari 500 g/l didapatkan pada 60 subyek penelitian. Berdasarkan uji statistik, skor Wells memiliki nilai kalibrasi yang kurang baik p < 0,01 dan nilai diskriminasi area under the curve AUC sangat lemah 47,4 . Kesimpulan: Skor Wells tidak dapat digunakan untuk memprediksi TVD pada pasien kanker yang tidak memiliki gejala dan tanda TVD. Proporsi pasien kanker dengan TVD tanpa gejala dan tanda trombosis adalah 2 . Kata Kunci: asimtomatik, kanker, skor Wells, trombosis vena dalam

---

ABSTRACT Background Venous thromboembolism is the main cause of morbidity and mortality in cancer patients. Until now there was no scoring system to predict deep vein thrombosis DVT in patients with risk factors but without sign and symptoms of thrombosis. Wells score was designated to predict patients who were clinically suspected as having DVT, but not yet used for patients who were asymptomatic. We investigate whether Wells score followed by ACCP IX guideline can be used to predict DVT in cancer asymptomatic patient. Purpose To investigate the use of Wells score in diagnosing DVT in asymptomatic cancer patients. Method We conducted a cross sectional study in cancer patients whose incidence of thrombosis were highest, without sign and symptoms of DVT. We calculated the Wells score from each patients and then chose the appropriate diagnostic examination in accordance to ACCP IX guideline. Result A total of 100 patients were enrolled in this research. We found the proportion of asymptomatic DVT in cancer patients was 2 . Most of the subjects has low Wells score 93 of subjects, score 2, categorized as unlikely and high D dimer 60 of subjects, concentration of 500 g l . Based on statistical test, Wells score had a poor calibration score p 0,01 and low area under the curve 47,4 . Conclusion Wells score cannot be used as a prediction model to predict DVT in asymptomatic cancer patients. The proportion of asymptomatic DVT in cancer patients was 2 . Keywords asymptomatic, cancer, deep vein thrombosis, Wells score "

"Latar belakang. Coronavirus disease-2019 (COVID-19) memiliki spektrum penyakit yang sangat luas dari gejala ringan sampai berat, hingga kematian. Reaksi inflamasi berat akibat dari COVID-19 ini menimbulkan gangguan hemostasis yang disebut dengan COVID-19 associated coagulopathy. Penelitian ini bertujuan untuk menilai profil koagulasi pada pasien dalam pemantauan (PDP) ataupun terkonfirmasi COVID-19 serta hubungannya terhadap mortalitas 30-hari pasien.Metode. Studi ini merupakan studi kohort retrospektif di RS Cipto Mangunkusumo (RSCM) selama Maret 2020 hingga Juni 2020. Sebanyak 106 subjek yang sesuai kriteria inklusi dianalisis dari data rekam medis. Dilakukan pengambilan data berupa data demografik, klinis atau hemodinamik pasien, profil koagulasi saat subjek ditentukan sebagai PDP atau terkonfirmasi COVID-19, pemberian terapi tromboprofilaksis heparin, dan status mortalitas 30 hari setelah admisi. Perhitungan statistik dilakukan dengan menggunakan Statistical Package of Social Science (SPSS) versi 24.0. Profil koagulasi subjek penyintas 30 hari dibandingkan dengan subjek yang mengalami mortalitas. Variabel profil koagulasi yang bermakna kemudian dianalisis dengan analisis bivariat dan regresi logistik multivariat.Hasil. Pada kelompok yang mengalami mortalitas 30-hari ditemukan adanya peningkatan jumlah leukosit (p: 0,022), penurunan kadar trombosit (p: 0,016), dan waktu protrombin (PT) dan waktu activated partial thromboplastin time (APTT) yang lebih panjang (p: 0,002 dan p: 0,018) dibandingkan pada kelompok penyintas 30-hari. Tidak ditemukan perbedaan fibrinogen dan d-Dimer yang bermakna secara statistik. PT merupakan suatu profil koagulasi tunggal yang dapat digunakan sebagai prediktor mortalitas 30-hari dengan odds ratio (95% CI) sebesar 1,407 (1,072 – 1,846), nilai p: 0,014.Simpulan. Terdapat hubungan antara faktor koagulasi pasien COVID-19 dengan mortalitas 30 hari di RSCM, khususnya PT yang dapat digunakan sebagai prediktor mortalitas 30-hari.

---

.Background. Coronavirus disease-2019 (COVID-19) has a very broad spectrum of disease from mild to severe symptoms, to death. The severe inflammatory reaction as a result of COVID-19 infection causes a hemostasis disorder called COVID-19 associated coagulopathy. This study aims to assess the coagulation profile of patients under monitoring (PDP) or confirmed COVID-19 and its relationship with 30-day mortality.

Method. This retrospective cohort study was conducted at RS Cipto Mangunkusumo (RSCM) from March 2020 to June 2020. A total of 106 subjects who met the inclusion criteria were analyzed from medical record data. Data were collected in the form of patient demographic, clinical or hemodynamic data, coagulation profile when the subject was determined as PDP or confirmed as COVID-19, administration of heparin thromboprophylaxis therapy, and mortality status 30 days after admission. Statistical calculations were performed using the Statistical Package of Social Science (SPSS) version 24.0. We compared the coagulation profiles of the survivor group in contrast to the non-survivor group. Significant coagulation profile variables were analyzed using bivariate analysis and multivariate logistic regression.

Results. There was elevated number of leukocytes (p: 0.022), reduced platelet levels (p: 0.016), and longer prothrombin time (PT) as well as activated partial thromboplastin time (APTT) (p: 0.002 and p: 0.018, consecutively) in non-survivor group. There were no statistical differences in fibrinogen and d-Dimer levels in both groups. Additionally, PT is a single coagulation profile which predicted 30-day mortality with an odds ratio (95% CI) of 1.407 (1.072 - 1.846), and p value: 0.014.

Conclusion. This present study shows abnormal coagulation results are associated with 30-day mortality in COVID-19 patients at RSCM. Prolonged PT was an independent predictor for 30-day mortality in COVID-19 patients"

"Setidaknya 1 dari 200 pasien COVID-19 akan mengalami DVT, dan sekitar 20% kasus VTE berhubungan dengan COVID-19. Risikonya meningkat empat kali lipat pada pasien COVID-19. Munculnya berbagai faktor patofisiologis yang berkontribusi terhadap terjadinya DVT pada pasien COVID-19 menimbulkan pertanyaan menarik mengenai perbedaan dalam karakteristik luaran pasien DVT sebelum dan selama pandemi, serta variasi dalam perawatan dan hasil pasien. Desain penelitian yang digunakan adalah studi kohort retrospektif untuk melihat perbandingan karakteristik dan manajemen pasien DVT (Deep Vein Thrombosis) sebelum dan selama pandemi COVID-19. Didapatkan data 489 subyek yang diikutsertakan dalam penelitian ini dengan nilai rata-rata usianya adalah 50.72 ± 18.00. Berdasarkan waktu terkenanya DVT, dari 489 subyek tersebut, sebagian besar sampel yaitu sebanyak 344 orang (72.9%) merupakan pasien yang mengalami DVT selama pandemi COVID. Berdasarkan status mortalitas, terdapat 336 orang (71.8%) yang masih hidup setelah mengalami DVT. Berdasarkan keberadaan perdarahan hebat, sebagian besar subyek yaitu 402 orang (82.2%) tidak mengalami perdarahan hebat. Berdasarkan status rekurensi, terdapat 321 orang (65.7%) yang mengalami rekurensi yaitu kembali dirawat dengan diagnosa yang sama dalam 1 tahun pertama setelah pertama kali dirawat. Sebanyak 479 orang (97.9%) tidak mengalami emboli paru. Didapatkan nilai rata-rata durasi rawat inap selama 13.41 ± 9.89 hari. Berdasarkan hasil pemeriksaan D-Dimer, didapatkan nilai rata-rata 3008.21 ± 1494.59 ng/mL. Sedangkan hasil pemeriksaan fibrinogen, didapatkan nilai rata-rata 301.06 ± 58.63 mg/dL. Dalam melihat komparasi data DVT sebelum dan selama pandemic COVID-19, dari 4 variabel yang dilihat, hanya D-Dimer yang memiliki perbedaan yang signifikan berupa peningkatan nilai rata-rata apabila dibandingkan antara sebelum pandemic COVID (2052.34 ± 568.30 ng/mL) dan selama COVID (3363.89 ± 1573.79 ng/mL) dengan nilai p < 0.001. Hasil berbeda terjadi pada fibrinogen yang tidak memiliki perbedaan yang signifikan antara sebelum pandemic COVID (295.66 ± 57.28 mg/dL) dibandingkan dengan selama COVID (303.06 ± 59.08 mg/dL) dengan nilai p 0.223. Ditemukan bahwa pada pasien COVID-19 didapati nilai D-Dimer yang lebih tinggi (nilai p <0.001) serta fibrinogen yang lebih tinggi secara signifikan (p=0.032).

---

At least 1 in 200 COVID-19 patients will experience DVT, and approximately 20% of VTE cases are related to COVID-19. The risk increases fourfold in COVID-19 patients. The emergence of various pathophysiological factors that contribute to the occurrence of DVT in COVID-19 patients raises interesting questions regarding differences in the outcome characteristics of DVT patients before and during the pandemic, as well as variations in patient care and outcomes. The research design used was a retrospective cohort study to compare the characteristics and management of DVT (Deep Vein Thrombosis) patients before and during the COVID-19 pandemic. Data were obtained for 489 subjects who were included in this study with an average age value of 50.72 ± 18.00. Based on the time of DVT, of the 489 subjects, the majority of the sample, namely 344 people (72.9%) were patients who experienced DVT during the COVID pandemic. Based on mortality status, there were 336 people (71.8%) who were still alive after experiencing DVT. Based on the presence of severe bleeding, the majority of subjects, namely 402 people (82.2%) did not experience severe bleeding. Based on recurrence status, there were 321 people (65.7%) who experienced recurrence, namely being treated again with the same diagnosis within the first year after first being treated. A total of 479 people (97.9%) did not experience pulmonary embolism. The average duration of hospitalization was 13.41 ± 9.89 days. Based on the results of the D-Dimer examination, an average value of 3008.21 ± 1494.59 ng/mL was obtained. Meanwhile, the results of the fibrinogen examination showed an average value of 301.06 ± 58.63 mg/dL. In looking at the comparison of DVT data before and during the COVID-19 pandemic, of the 4 variables looked at, only D-Dimer had a significant difference in the form of an increase in the average value when compared between before the COVID pandemic (2052.34 ± 568.30 ng/mL) and during COVID (3363.89 ± 1573.79 ng/mL) with p value < 0.001. Different results occurred in fibrinogen which did not have a significant difference between before the COVID pandemic (295.66 ± 57.28 mg/dL) compared to during COVID (303.06 ± 59.08 mg/dL) with a p value of 0.223. It was found that COVID-19 patients had higher D-Dimer values (p value <0.001) and significantly higher fibrinogen (p=0.032)."

"Latar Belakang: Deep Vein Thrombosis (DVT) adalah salah satu penyakit penyebab mortalitas jangka pendek dan morbiditas jangka panjang. Kasus DVT akan meningkat seiring bertambahnya usia. Pada pasien dengan keganasan, risiko DVT meningkat hingga 4,1 kali lipat karena kondisi hiperkoagulasi. Penatalaksanaan DVT antara lain pemberian antikoagulan dan kompresi eksterna. Penelitian ini bertujuan membandingkan luaran antropometrik tungkai pasien DVT dengan keganasan dan non-keganasan yang diterapi heparin.Metode: Kohort retrospektif menggunakan rekam medis di RS Cipto Mangunkusumo. Variabel bebas adalah status keganasan pada pasien DVT sedangkan variabel terikatnya adalah pengukuran antropometrik lingkar tungkai sebelum terapi heparin, 4 hari, dan 7 hari. Analisis statistik menggunakan SPSS versi 25, nilai p<0,05 menunjukkan kemaknaan secara statistik.Hasil: Sebanyak 63 subjek penelitian, didapatkan subjek DVT dengan keganasan sebanyak 33 subjek (52,4%) dan DVT non keganasan sebanyak 30 subjek (47,6%). Pada awal terapi, tidak terdapat perbedaan ukuran antropometrik antara DVT keganasan dan non keganasan. Pada hari ke-4 dan ke-7 terapi, terdapat perbedaan perbaikan ukuran antropometrik di mid femur, distal femur, dan mid cruris, dimana perbaikan klinis lebih tampak pada DVT non keganasan (p<0,05). Subjek DVT keganasan memiliki dosis heparin maintenance teraputik yang lebih tinggi (p=0,000), dan mencapai waktu kadar APTT terapeutik yang lebih lama (p=0,000).Kesimpulan: Subjek DVT keganasan menunjukkan perbaikan klinis yang lebih kecil dibandingkan DVT non keganasan. Selain itu, memerlukan dosis heparin maintenance terapeutik yang lebih tinggi, dan mencapai waktu kadar APTT terapeutik yang lebih lama.

---

Background: Deep Vein Thrombosis (DVT) is a disease that causes short-term mortality and long-term morbidity. DVT cases will increase with age. In patients with malignancy, the risk of DVT increases up to 4.1-fold due to the hypercoagulable state. Treatment for DVT includes anticoagulants and external compression. This study aims to compare the anthropometric outcomes of the limbs of DVT patients with malignancy and non-malignancy treated with heparin.

Method: Retrospective cohort study using medical records at Cipto Mangunkusumo Hospital. The independent variable is malignancy status in DVT patients while the dependent variable is anthropometric measurements of leg circumference at first day, 4 days and 7 days heparin therapy. Statistical analysis using SPSS version 25, p<0.05 showed statistical significance.

Results: Of the 63 study subjects, 33 subjects (52.4%) had DVT with malignancy and 30 subjects (47.6%) had non-malignant DVT. At the start of therapy, there was no difference in anthropometric measures between malignant and non-malignant DVT. On the fourth and seventh days of therapy, there were differences in anthropometric size improvement in the mid femur, distal femur, and mid cruris, whereas clinical improvement was more evident in nonmalignant DVT (p<0.05). Malignant DVT subjects had higher therapeutic maintenance heparin doses (p=0.000), and achieved longer therapeutic APTT levels (p=0.000).

Conclusion: Malignant DVT subjects showed less clinical improvement than non-malignant DVT. In addition, it requires higher therapeutic maintenance heparin doses, and achieves a longer therapeutic APTT level time."

"Latar belakang: Kondisi badai sitokin atau hiperinflamasi pada COVID-19 dapat berakibat fatal pada pasien. Inflamasi juga dapat menyebabkan gangguan koagulasi. Rasio netrofil limfosit (RNL) dan rasio platelet limfosit (RPL) telah diketahui dapat menjadi penanda inflamasi pada beberapa penyakit. Status koagulasi pasien dapat dilihat dari parameter nilai D-dimer. Peran penanda hayati yang dapat menggambarkan keadaan tromboinflamasi pada pasien COVID-19 tersebut perlu ditelaah lebih lanjut. Tujuan penelitian: Mengetahui hubungan nilai RNL, RPL dan D-dimer terhadap luaran tatalaksana pasien COVID-19 terkonfirmasi di RSUP Persahabatan.Metode penelitian: Analisis observasional kohort retrospektif terhadap pasien COVID-19 terkonfirmasi yang dirawat di RSUP Persahabatan secara total sampling diperoleh dari bulan Maret sampai dengan Juli 2020. Kami meninjau 214 rekam medis pasien COVID-19 terkonfirmasi yang memenuhi kriteria inklusi. Hasil penelitian: Rerata usia pasien pada penelitian ini adalah 54,35 tahun, didominasi oleh laki-laki sebanyak 60,7%. Status gizi pasien paling banyak adalah normal sebesar 54,7%. Proporsi pasien yang memiliki komorbid sebanyak 65,4%. Komorbid yang paling banyak adalah hipertensi, kedua adalah diabetes melitus. Derajat penyakit paling banyak adalah berat-kritis sebanyak 76,1%, diikuti sedang 20,1%, ringan 3,7%. Median lama rawat adalah 12 hari. Pasien meninggal sebanyak 60 orang (28%). Nilai median RNL, RPL dan D-dimer awal pasien adalah 5,75 (0,68-81,5), 243,5 (44,7-1607) dan 1140 (190-141300), secara berurutan. Terdapat hubungan antara nilai RNL (p=0,000), RPL (0,013) dan D-dimer (0,032) terhadap luaran pasien. Kesimpulan: Nilai RNL, RPL dan D-dimer awal perawatan pasien COVID-19 terkonfirmasi di RSUP Persahabatan berhubungan dengan luaran tatalaksana pasien.

---

Backgrounds: Cytokine storm or hyperinflammation in COVID-19 can cause fatal outcome for patients. Imflammation also can cause hypercoagulation. Neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) have already known as inflammation marker in several diseases. Coagulation status in patients could be measured by D-dimer value. The role of biomarkers for that thromboinflammation in COVID-19 should be explored.

Aims: to know the association between NLR, PLR and D-dimer value with confirmed COVID-19 patients’ outcome in Persahabatan hospital, Jakarta

Methods: We performed observational retrospective cohort analysis of confirmed COVID-19 patients hospitalized in Persahataban hospital. Subjects by means of total sampling were confirmed COVID-19 patients between March till July 2020. We reviewed the medical record of 214 patients whom met the inclusion criteria.

Results: Mean age of patients in this study were 54,35 years old, dominated by males (60,7%). Most of the patients were with normal nutritional status (54,7%) and presented with comorbidity (65,4%). Diabetes melitus was the most frequent comorbidity, second was hypertension. Disease severity was severe to critical in 76,1% patients, 20,1% in moderate cases and 3,7% in mild case. Length of hospital stay was 12 days. Death patients were 60 (28%). The median of initial NLR, PLR and D-dimer value were 5,75 (0,68-81,5), 243,5 (44,7-1607) dan 1140 (190-141300), respectively. There were an association between NLR (p=0,000), PLR (0,013) and D-dimer value (p=0,032) with patients’ outcome.

Conclusions: There were association between NLR, PLR and D-dimer value on admission with confirmed COVID-19 patients’ outcome in Persahabatan hospital."

"ABSTRAKLatar Belakang. Penegakan diagnosis DVT akut ekstremitas bawah dengan sarana diagnostik yang ada termasuk venous duplex ultrasonography VDUS masih terkendala biaya, waktu dan tenaga operator. Penelitian ini bertujuan menilai efektivitas skor Wells, kadar D-Dimer atau skor kombinasi keduanya dibandingkan dengan VDUS dalam mendeteksi kasus-kasus DVT akut ekstremitas bawah.Metode. Dilakukan studi diagnostik dengan desain cross-sectional yang dilakukan di Divisi Bedah Vaskular dan Endovaskular Departemen Ilmu Bedah FKUI-RSCM pada semua pasien dewasa dengan dugaan DVT akut ekstremitas bawah yang dikonsultasikan ke Divisi Bedah Vaskular RSCM yang dikonfirmasi dengan pemeriksaan VDUS pada periode Januari 2014 ndash; Desember 2015 yang memenuhi kriteria inklusi dan eksklusi. Sumber data diambil dari rekam medik data sekunder . Analisis data berupa uji diagnostik dan diuji dengan SPSS version 17.0 for WindowsHasil. Studi melibatkan 85 orang. Didapatkan kejadian DVT akut ekstremitas bawah sebesar 65,88 . Sensitivitas dan nilai duga negatif tertinggi 100.00 didapatkan pada skor kombinasi II dan IV. Sedangkan spesifisitas tertinggi 89,66 dan nilai duga positif tertinggi 92,68 diperoleh pada skor kombinasi III. Skor dengan nilai diagnostik berimbang sensitivitas 87,50 ; spesifisitas 72,41 dijumpai pada skor Wells 3 level I.Simpulan. Skor Wells dan VDUS memiliki efektivitas sebanding dalam deteksi kasus-kasus kecurigaan DVT akut ekstremitas bawah.

---

ABSTRACTIntroduction. The diagnosis of acute lower extremity DVT with available resources including VDUS was still costly, time consuming and power consumng. The purpose of this study was to evaluate effectivity of Wells score, D Dimer and combination of both compared with VDUS in detecting lower extremity DVT. Methods. This was a cross sectional diagnostic study that was carried out at Vascular and Endovascular Surgery Division of Surgery Department of FKUI RSCM between by enrolling all adult patients with suspected acute DVT of lower extremity that was consulted to Vascular Surgery Division and confirmed with VDUS study between January 2014 and December 2015 that meet inclusion and exclusion criteria. Data source was taken from medical record. Data analysis in the form of diagnostic study was performed with SPSS version 17.0 for WindowsResult. The study enrolled 85 subjects, of which 65,88 was found to have acute lower extremity DVT. The highest sensitivity and negative predictive value 100,00 was discovered in combination score II and IV. The combination score III had the highest specificity 89,66 and positive predictive value 92,68 . Whereas the most balanced diagnostic study score was the Wells score 3 Level I with sensitivity 87,50 and specificity 72,41 . Conclusion. Wells score and VDUS were equally effective in detection of lower extremity acute DVT cases. "

"Pendahuluan: Heparin dapat digunakan sebagai terapi bagi pasien COVID-19. Namun, indikasi dan efeknya masih berbeda di berbagai penelitian. Oleh karena itu, penelitian ini bertujuan untuk menilai efektivitas pemberian heparin dalam menurunkan keparahan gejala klinis. Metode :Studi retrospektif dilakukan dari rekam medis pasien COVID-19 kondisi sedang-berat yang dirawat di Rumah Sakit Universitas Indonesia (RSUI). Parameter yang diperiksa adalah kondisi klinis pasien (tingkat mortalitas dan total lama perawatan), kadar D-dimer, dan trombosit pada dua kelompok, kelompok yang diberikan heparin dan yang tidak. Hasil:Penelitian ini menyertakan 110 subjek penelitian. Terdapat tingkat mortalitas yang lebih tinggi pada kelompok heparin dibandingkan kontrol (45,3% vs 5 10,9%; p<0,01). Hal ini dapat disebabkan perbedaan derajat sedang dan berat. Mayoritas kelompok heparin berkondisi berat (58,1% vs 28,2%) jika dibandingkan kontrol. Pada pengecekan laboratorium, heparin menurunkan kadar D-dimer (790 ke 500 vs 725 ke 4.475 µg/L) dan trombosit (366 ke 208x103 vs 217 ke 318x103/µL)secara signifikan (p<0,01). Kesimpulan: Kelompok heparin memiliki tingkat mortalitas yang tinggi akibat tingkat kondisi yang lebih berat, tetapi kadar D-dimer dan trombosit menurun dibandingkan kelompok kontrol.

---

Introduction: Heparin can be used as therapy for COVID-19 patients. However, the indications and effects still differ in various studies. Therefore, this study aims to assess the effectiveness of heparin administration in reducing the severity of clinical symptoms. Methods: A retrospective study was conducted from medical records of moderate-severe COVID-19 patients treated at the University of Indonesia Hospital (RSUI). The parameters examined were the patient's clinical condition (mortality rate and total length of treatment), D-dimer levels, and platelets in two groups, those given heparin and those not. Results: This study included 110 research subjects. There was a higher mortality rate in the heparin group compared to controls (45.3% vs 5 10.9%; p<0.01). This is due to the difference in moderate and severe degrees. The majority of the heparin group had severe conditions (58.1% 28.2%) when compared to controls. In laboratory tests, heparin reduced the levels of D-dimer (790 to 500 vs 725 to 4,475 µg/L) and platelets (366 to 208x103 vs 217 to 318x103/µL) significantly (p<0.01). Conclusion: The heparin group had a high mortality rate due to more severe conditions, but D-dimer and platelet levels decreased compared to the control group"

"Latar Belakang: Penggunaan heparin inhalasi pada beberapa penelitian COVID-19memberikan hasil dalam perbaikan klinis pasien, baik dalam menurunkan lama rawat,perbaikan oksigenasi paru, dan mortalitas. Dosis harian total heparin inhalasi yangbervariasi terutama bila diberikan bersamaan dengan antikoagulan sistemik, memilikiresiko komplikasi perdarahan yang memerlukan kajian terhadap keefektifan dankeamanannya.Tujuan: Meneliti keefektifan dan keamanan inhalasi heparin dosis 150,000 IU/haridengan dosis 100.000 IU/hari dinilai dari AaDO2, aPTT dan d-Dimer dalam 7 haripengamatan pada pasien ICU COVID-19.Metode: Penelitian ini merupakan penelitian observasional dengan studi kohortretrospektif menggunakan data sekunder rekam medis pasien ICU COVID-19 bulanSeptember 2020 – September 2021. Terdapat 300 sampel menggunakan consecutivesampling. Pasien dikelompokkan menjadi kelompok heparin dosis 150.000 IU/hari dan100.000 IU/hari. Pencatatan dilakukan dalam 7 hari pengamatan. Uji Statistikmenggunakan uji Mann Whitney untuk menilai tingkat keparahan, Uji Wilcoxon rank testuntuk melihat perbedaan variabel dependen hari pertama dengan hari ketujuh padamasing-masing dosis.Hasil: Heparin inhalasi baik dosis 150.000 IU/hari dan 100.000 IU /hari bermaknamenurunkan AaDO2 pada 7 hari pengamatan (p 0.001). Nilai aPTT tidak memanjangpada kedua kelompok, dan kedua dosis heparin sama- sama menurunkan nilai d-Dimerpada 7 hari pengamatan (p 0.001).Simpulan: Heparin Inhalasi dosis 150.000 IU/hari sama efektif dinilai dari AaDO2, dansama amannya terhadap aPTT dan d-Dimer dibandingkan heparin inhalasi dosis 100.000IU/hari.

---

Rationale: The use of inhaled heparin in several COVID-19 studies has resulted in

clinical improvements in patients, both in reducing length of treatment, improving

pulmonary oxygenation, and reducing mortality. The varying total daily dose of inhaled

heparin, especially when given together with systemic anticoagulants, poses a risk of

bleeding complications that require review of its effectiveness and safety.

Objective: To analyze effectiveness and safety of heparin inhalation dosage 150,000

IU/day compare to 100,000 IU/day assessed from AaDO2, aPTT and d-Dimer from 7

days observation in ICU COVID-19 patients with invasive and non-invasive ventilator

patterns.

Methods: An observational cohort retrospective study used secondary data from medical

records ICU COVID-19 patients with invasive and noninvasive ventilator patterns from

September 2020 – September 2021. There were 300 samples using consecutive sampling.

Patients divided into 2 groups, one received dosage 150,000 IU / day heparin inhalation,

the other received heparin inhalation dosage 100,000 IU / day. Recording of the research

from medical records is carried out at 7 days of ICU treatment. Statistical tests were

carried out using Mann Whitney to assess severity, Wilcoxon rank test to see the

difference in dependent variables day 1 and day 7 to dose.

Measurements and Main Results: Heparin inhalation at dose of 150,000 IU/day and

100,000 IU/day both significantly decreased AaDO2 at 7 days of observation (p 0.001).

The aPTT on both groups at 7 days of observation are within normal limits. Both doses

of heparin inhalation decreased d-dimer at 7 days of observation (p 0.001).

Conclusion: Inhaled heparin doses of 150,000 IU/day as effective and as safe as inhaled

heparin doses of 100,000 IU/day."